Last reviewed · How we verify
Routine paediatric vaccine - Hepatitis A
Routine paediatric vaccine - Hepatitis A is a inactivated viral vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of hepatitis A infection in pediatric patients. Also known as: Hepatitis A.
Hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.
Hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A infection in pediatric patients.
At a glance
| Generic name | Routine paediatric vaccine - Hepatitis A |
|---|---|
| Also known as | Hepatitis A |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | inactivated viral vaccine |
| Target | Hepatitis A virus antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated hepatitis A virus antigen that triggers both humoral (antibody) and cellular immune responses. This leads to the production of anti-HAV antibodies that neutralize the virus upon exposure, preventing infection and disease. The vaccine is typically given as a two-dose series to establish long-term immunity.
Approved indications
- Prevention of hepatitis A infection in pediatric patients
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Headache
- Fatigue
- Loss of appetite
Key clinical trials
- Baby Vaccine Study (Sched3) (PHASE2)
- Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Routine paediatric vaccine - Hepatitis A CI brief — competitive landscape report
- Routine paediatric vaccine - Hepatitis A updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Routine paediatric vaccine - Hepatitis A
What is Routine paediatric vaccine - Hepatitis A?
How does Routine paediatric vaccine - Hepatitis A work?
What is Routine paediatric vaccine - Hepatitis A used for?
Who makes Routine paediatric vaccine - Hepatitis A?
Is Routine paediatric vaccine - Hepatitis A also known as anything else?
What drug class is Routine paediatric vaccine - Hepatitis A in?
What development phase is Routine paediatric vaccine - Hepatitis A in?
What are the side effects of Routine paediatric vaccine - Hepatitis A?
What does Routine paediatric vaccine - Hepatitis A target?
Related
- Drug class: All inactivated viral vaccine drugs
- Target: All drugs targeting Hepatitis A virus antigen
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of hepatitis A infection in pediatric patients
- Also known as: Hepatitis A
- Compare: Routine paediatric vaccine - Hepatitis A vs similar drugs
- Pricing: Routine paediatric vaccine - Hepatitis A cost, discount & access